Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion

Dow Jones – HealthWednesday, October 15, 2025 at 3:25:00 PM
PositiveHealth
Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion
Novo Nordisk's recent agreement to acquire the blood disease drug zaltenibart from Omeros for up to $2.1 billion marks a significant step in expanding its portfolio. This deal not only highlights Novo Nordisk's commitment to addressing critical health issues but also positions them to potentially lead in the treatment of blood diseases. The exclusive global rights to develop and commercialize zaltenibart could pave the way for innovative therapies, benefiting patients and enhancing the company's market presence.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Health Care Roundup: Market Talk
NeutralHealth
In the latest Market Talks, insights are shared on key players in the Health Care sector, including Novo Nordisk, AstraZeneca, and Hikma Pharmaceuticals. This roundup is important as it provides investors and stakeholders with valuable information on market trends and company performances, helping them make informed decisions.